Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
4
Neutral
6
Bullish
4
Bearish
30
Neutral
6
Bullish
10
Bearish
26
Neutral
0
Bullish
6
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
3B BlackBio DX Limited is an Indian biotech and diagnostics company focused on molecular diagnostics (TRUPCR PCR kits, enzymes and reagents), Next‑Gen Sequencing assays (TRUNGS), and rapid tests (TRURAPID), while retaining legacy agrochemical operations; the company recently acquired Coris BioConcept (Belgium) and operates manufacturing and R&D facilities recognized by DSIR and ISO standards.
Management reported consolidated nine‑months revenue of INR99.06 crore (including Coris) versus INR64.80 crore earlier, with 3B standalone growing around 11.8% year‑on‑year and management guiding consolidated revenue growth of 10%–15% for the full year, while exports are expected to outpace domestic growth at 15%–20% given strengthened European and other geographies.
The Coris acquisition materially changes revenue composition and capabilities: Coris contributed approximately INR24 crore in the quarter, including a ~INR8.8 crore one‑off from a HAT government supply contract, and management is pursuing US FDA clearance and selective IVDR certifications to convert regulatory investment into market access for Europe and the US.
Competition intensity is rising as adjacent diagnostic players enter molecular diagnostics attracted by higher margins, but 3B emphasizes SKU breadth, technical support, and workflow efficiency to retain stickiness; management is balancing organic R&D (multiplex panels, dPCR, sample‑to‑answer) with inorganic growth via acquisitions to protect and expand market share.
The company holds cash and acquisition firepower (management cited roughly INR190 crore cash position with INR130–140 crore available for acquisitions while retaining reserves), intends to prioritize profitable scale and M&A integration, and flags short‑term EBITDA pressure from merger‑related one‑offs while targeting improved profitability at Coris next year.
Healthcare Services
Healthcare Service Provider
1,068 Cr
High Risk
18.2
57.2
0.2
3.6
1,750.00
1,110.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Discovery themes featuring this stock3B Blackbio DX Ltd (3BBLACKBIO) is currently trading at 1,244.05 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
3B BlackBio DX Limited is an Indian biotech and diagnostics company focused on molecular diagnostics (TRUPCR PCR kits, enzymes and reagents), Next‑Gen Sequencing assays (TRUNGS), and rapid tests (TRURAPID), while retaining legacy agrochemical operations; the company recently acquired Coris BioConcept (Belgium) and operates manufacturing and R&D facilities recognized by DSIR and ISO standards. Management reported consolidated nine‑months revenue of INR99.06 crore (including Coris) versus INR64.80 crore earlier, with 3B standalone growing around 11.8% year‑on‑year and management guiding consolidated revenue growth of 10%–15% for the full year, while exports are expected to outpace domestic growth at 15%–20% given strengthened European and other geographies. The Coris acquisition materially changes revenue composition and capabilities: Coris contributed approximately INR24 crore in the quarter, including a ~INR8.8 crore one‑off from a HAT government supply contract, and management is pursuing US FDA clearance and selective IVDR certifications to convert regulatory investment into market access for Europe and the US. Competition intensity is rising as adjacent diagnostic players enter molecular diagnostics attracted by higher margins, but 3B emphasizes SKU breadth, technical support, and workflow efficiency to retain stickiness; management is balancing organic R&D (multiplex panels, dPCR, sample‑to‑answer) with inorganic growth via acquisitions to protect and expand market share. The company holds cash and acquisition firepower (management cited roughly INR190 crore cash position with INR130–140 crore available for acquisitions while retaining reserves), intends to prioritize profitable scale and M&A integration, and flags short‑term EBITDA pressure from merger‑related one‑offs while targeting improved profitability at Coris next year.
Over the past 52 weeks, 3B Blackbio DX Ltd has traded between a low of ₹1,110.00 and a high of ₹1,750.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
3B Blackbio DX Ltd has a market capitalization of approximately 1,067.73. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
3B Blackbio DX Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 18.22 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,067.73 Cr, 3B Blackbio DX Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
3B Blackbio DX Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of 3B Blackbio DX Ltd is 18.22. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
540.00 | 1,780 Cr | 17.54 | 1.82 | 0.00 | 10.35 | 10.42 | 5.56 | ||
285.00 | 1,486 Cr | 46.17 | 6.07 | 0.00 | 13.15 | 14.38 | 7.01 | ||
1244.05 | 1,068 Cr | 18.22 | 3.58 | 0.40 | 18.06 | 23.58 | 15.85 | ||
305.05 | 970 Cr | 37.29 | 1.42 | 0.00 | -0.30 | -4.66 | 2.89 | ||
445.35 | 870 Cr | 13.98 | 8.59 | 0.00 | 43.51 | 58.07 | 27.58 | ||
116.40 | 847 Cr | 34.58 | 5.56 | 0.00 | 16.08 | 20.18 | 12.69 | ||
243.35 | 595 Cr | 21.93 | 4.31 | 0.00 | 18.69 | 20.84 | 10.52 | ||
| Median: 7 Co. | — | 305.05 | 970 Cr | 21.93 | 4.31 | 0.00 | 16.08 | 20.18 | 10.52 |
Results & Dividend
Board approved audited standalone and consolidated results for FY ended 31 Mar 2026 (auditor issued unmodified opinion), recommended final dividend of Rs.5.00/share (50%) subject to AGM approval, and appointed Ali Jain & Sharma as internal auditor for FY2026‑27.
Investor Presentation
Filed investor presentation with consolidated FY 2025-26 and Q4 highlights (revenue ₹14,191.81L; PAT ₹5,992.98L; EPS ₹69.94), notes Coris Bioconcept acquisition contribution and division updates for Agrochemicals and MDx.
Results & Dividend
3B BlackBio Dx Ltd approved audited standalone & consolidated results for Q4/FY2025-26 with unmodified audit opinion, recommended a final dividend of Rs.5.00 per share (50%) subject to shareholder approval, and appointed Ali Jain & Sharma as internal auditor for FY2026-27.
Earnings Conference Call
3B BlackBio DX will hold an earnings conference call on 1 June 2026 at 4:00 PM IST to discuss operational and financial results for Q4 and FY ended 31 March 2026; dial‑in details and management speakers provided.
Earnings Concall
3B BlackBio Dx Ltd will host an earnings conference call on 1 June 2026 at 4:00 PM IST to discuss operational and financial results for Q4 and FY ended 31 Mar 2026; dial-in and international toll‑free details provided.
